| Income Statement | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 |
|---|---|---|---|---|
| Research and development expenses | 901,144 | -274,634.5* | 619,693 | 651,784 |
| General and administrative expenses | 11,284,550 | 5,424,982* | 1,224,546 | 2,012,120 |
| Total operating expenses | 12,185,694 | 5,150,347.5 | 1,844,239 | 2,663,904 |
| Loss from operations | -12,185,694 | -5,150,347.5* | -1,844,239 | -2,663,904 |
| Unrealized gain (loss)from changes in fair value of digital assets | -22,078,601 | 453,087* | NaN | NaN |
| Realized gain on sale of digital assets | 15,100 | 5,597,696.5* | NaN | NaN |
| Trading gains, net | 2,029 | 24.25* | NaN | NaN |
| Foreign currency gains/(losses), net | -1,567 | -130.25* | NaN | NaN |
| Change in fv of warrant liability | NaN | 11,188.5* | -12,859 | -9,518 |
| Change in fv of derivative | -48,279 | -13,786.5* | NaN | NaN |
| Interest income | 7 | 85.5* | 56,426 | 15,247 |
| Interest expense | 859,405 | 238,978.5* | 6,301 | 23,054 |
| Total other income (expense) | -22,874,158 | 5,814,382.5* | 62,984 | 1,711 |
| Net gain | -35,059,852 | 664,035 | -1,781,255 | -2,662,193 |
| Basic EPS | -2.26 | 0.068 | -0.14 | -0.26 |
| Diluted EPS | -2.26 | 0.068 | -0.14 | -0.26 |
| Basic Average Shares | 15,513,389 | 9,700,611 | 12,575,983 | 10,369,127 |
| Diluted Average Shares | 15,513,389 | 9,700,611 | 12,575,983 | 10,369,127 |
Apimeds Pharmaceuticals US, Inc. (APUS)
Apimeds Pharmaceuticals US, Inc. (APUS)